Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTP86E2)

• DTT Name: Plasminogen (PLG) DTT Info
• Gene Name: PLG

Molecule-Related Drug & Molecule List

8 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[1]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[2]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[3]
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[4]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[5]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[6]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[1]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[7]

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[8]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[9]
Plasminogen	DM0EFQS	Alzheimer disease	8A20	Phase 2/3	[10]
BIIB131	DMDG3AD	Acute ischemic stroke	8B11	Phase 2	[11]
RetinoStat	DMVXZJ4	Macular degeneration	9B78.3	Phase 2	[12]
Troplasminogen alfa	DMR8Y4F	Myocardial infarction	BA41-BA43	Phase 2	[13]
bis-triazole derivative 10	DMN2EI1	Otitis media	AA80-AB0Z	Clinical trial	[14]

12 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione	DM69T3A	Discovery agent	N.A.	Investigative	[15]
1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione	DMNZYWR	Discovery agent	N.A.	Investigative	[15]
1-guanidino-7-isoquinolinesulphonamide	DM48TIN	Discovery agent	N.A.	Investigative	[16]
1-guanidino-N-phenyl-7-isoquinolinesulphonamide	DMTF1HL	Discovery agent	N.A.	Investigative	[16]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[17]
Bicine	DMTRDPI	Discovery agent	N.A.	Investigative	[18]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[19]
M5	DM3IX2E	Cerebrovascular ischaemia	8B1Z	Investigative	[4]
N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine	DMNO46U	Discovery agent	N.A.	Investigative	[20]
SMTP-0	DM9SF48	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
Textilinin	DMHBMJZ	Bleeding disorder	GA20-GA21	Investigative	[4]
XP-21510	DMGOMYN	Menorrhagia	GA20.50	Investigative	[4]

References

• [1] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [2] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [3] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [4] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [5] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [6] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [7] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [8] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
• [9] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [10] Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
• [11] Clinical pipeline report, company report or official report of Biogen
• [12] Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
• [13] V-10153 (Vernalis). Curr Opin Investig Drugs. 2005 Sep;6(9):951-5.
• [14] A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem. 2012 Feb 9;55(3):1171-80.
• [15] Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.
• [16] Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51.
• [17] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [18] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [19] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [20] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.